Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 970.85M |
| Revenue (ttm) | 308.77M |
| Net Income (ttm) | 325.58K |
| Shares Out | 685.15M |
| EPS (ttm) | 0.00 |
| PE Ratio | 2,981.93 |
| Forward PE | 24.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,674,849 |
| Average Volume | 21,154,271 |
| Open | 1.441 |
| Previous Close | 1.417 |
| Day's Range | 1.421 - 1.483 |
| 52-Week Range | 0.656 - 1.505 |
| Beta | 0.19 |
| RSI | 63.10 |
| Earnings Date | Nov 6, 2025 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
Financial Performance
In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.
Financial numbers in USD Financial StatementsNews
Pharming Group N.V. (PHAR) Presents at Jefferies London Healthcare Conference 2025 - Slideshow
2025-11-19. The following slide deck was published by Pharming Group N.V.
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 300 points on Wednesday. Shares of Pharming Group N.V. (NASDAQ: PHAR) rose sharply during Wednesday's session after the company repo...
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Pharming Group (PHGUF) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Adjustments
Pharming Group (PHGUF) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Adjustments
Q3 2025 Pharming Group NV Earnings Call Transcript
Q3 2025 Pharming Group NV Earnings Call Transcript
Pharming Group N.V. 2025 Q3 - Results - Earnings Call Presentation
What To Expect From Pharming Group (XAMS:PHARM) Q3 2025 Earnings
What To Expect From Pharming Group (XAMS:PHARM) Q3 2025 Earnings
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Health...
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming to report third quarter 2025 financial results and provide a business update on November 6, 2025, and host conference call at 13:30 CET/07:30 ET.
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10
Pharming Group provides update on previously announced G&A expense reduction plan
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to acc...
FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted
(RTTNews) - Pharming Group N.V. (PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for leniolisib, an oral, selective PI3Kd inhibitor, as a ...
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based o...
Pharming Group promoted to the Euronext AMX® index
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small ...
Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th A...
Pharming Group names new finance head
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Offic...
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):... • news
Pharming Group to participate in August investor conference
Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conf...
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second ...